News
Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and 5% lower for operating profit than expected, reflects lower GLP-1 penetration in the US market.
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...
Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...
In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...
Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback